Loading stock data…
$20.29+0.77 (+3.94%)
Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens.
Pelthos Therapeutics Inc. in the Healthcare sector is trading at $20.29 with a market capitalization of $78M. Wall Street consensus targets $51.71 (7 analysts), implying a +154.9% move over the next 12 months. The stock is currently near its 52-week low of $18.19, remaining 18.3% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 28 is oversold, raising the odds of a near-term bounce. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $15.60M↑ | $10.91M↑ | $9.39M↑ | $7.41M | $0 |
| Gross Profit | $2.77M↓ | $5.59M↑ | $5.00M↑ | $2.43M | $0 |
| Operating Income | -$17.32M↓ | -$13.09M↓ | -$12.00M↑ | -$15.36M↓ | -$3.23M |
| Net Income | -$23.42M↑ | -$25.07M↓ | -$21.66M↓ | -$16.24M↓ | -$3.45M |
Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 y...